found Documents: 719

Announcements & Press Releases, Oncology / Immunology | 20 Sep 2021

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

2 items

— Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors — Hong Kong, Shanghai & Florham Park,

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Sep 2021

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Sep 2021

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

2 items

— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, September 8,

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Sep 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMP

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Group | 6 Sep 2021

HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary shares, which trade on The Stock Exchange of Hong Kong Limit

LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 2 Sep 2021

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

2 items

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 1, 2021, it granted share options under the Share Option Scheme adopted by HUT

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 1 Sep 2021

Monthly Return

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Aug 2021

Total Voting Rights

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, August 31, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 31, 2021, the issued share capital of HUTCHMED consisted of 8

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 26 Aug 2021

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 26, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 23 Aug 2021

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Ha

HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Electronic Communication of Corporate Information

2 items

Hong Kong, Shanghai & Florham Park, NJ — August 17, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that it has written to its shareholders regarding its intention to adopt electronic c

LSE RNS Announcement (PDF)Letter to UK shareholders (PDF)

Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Election of language and means of receipt of corporate communications

3 items

HKEX Announcement (PDF)Letter and reply form to new registered shareholders (PDF)Notification letter and request form to non-registered holders (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Aug 2021

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

2 items

- Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio - - Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milesto

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 4 Aug 2021

Monthly Return

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jul 2021

Total Voting Rights

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Friday, July 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at July 30, 2021, the issued share capital of HUTCHMED consisted of 864,11

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Jul 2021

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Group | 28 Jul 2021

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

2 items

ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for surufatinib both accepted Raised $615m2 gross pr

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Jul 2021

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

2 items

— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification — Hong Kong, Shanghai & Florham Park, NJ —

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Jul 2021

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, July 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period in connection with the Global Offering ended on J

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 16 Jul 2021

TR-1: Standard form for notification of major holdings

2 items

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

2 items

– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Jul 2021

TR-1: Standard form for notification of major holdings

2 items

HKEX Overseas Regulatory Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2021

Monthly Return

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Jul 2021

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

2 items

Hong Kong, Shanghai and Florham Park, NJ — Tuesday, July 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL‑295, its investigative and highly selective oral inhibitor of ERK, which

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 2 Jul 2021

TR-1: Standard form for notification of major holdings

2 items

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 2 Jul 2021

HUTCHMED to Announce 2021 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, July 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jul 2021

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

2 items

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – Hong Kong, Shanghai & Florham Park, NJ — Thursday,

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jun 2021

Total Voting Rights

2 items

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at June 30, 2021, the issued share capital of HUTCHMED consisted of 848,51

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jun 2021

Holdings in Company

2 items

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) announces that, in connection with its global offering (the "Global Offering") of 104,

HKEX Overseas Regulatory Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 30 Jun 2021

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordinary shares (“Shares”) on the Main Board of the Stoc

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

Blocklisting Six Monthly Return

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, June 29, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant:

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

List of Directors and Their Roles and Functions

1 item

Download List of Directors and Role and Function (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Group | 23 Jun 2021

HUTCHMED Announces Pricing of Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the “Global Offering”) of 104,000,000 n

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Jun 2021

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

2 items

– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor – Hong Kong, Shanghai & Florham Park, NJ —Tuesday, June 22, 202

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Jun 2021

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

2 items

– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET – Hong K

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 18 Jun 2021

Disclosure Update

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kon

View Announcement (PDF)

Announcements & Press Releases, Group | 18 Jun 2021

HUTCHMED Launches Hong Kong Initial Public Offering

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the “Hong Kong Public Offering”),

View Announcement (PDF)

Announcements & Press Releases, Group | 20 May 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

1 item

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 8 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update – Hong Kong,

Download Press Release (PDF)

Announcements & Press Releases, Group | 17 May 2021

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

1 item

– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones – Hong Kong, Shanghai & Florham Park, NJ — Monday, May 17, 2021: HUTCHMED (China) Limited (“HUTCHME

Download Press Release (PDF)

Announcements & Press Releases, Group | 7 May 2021

HUTCHMED to Attend Upcoming Investor Conferences

1 item

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat a

Download Press Release (PDF)

Announcements & Press Releases, Group | 4 May 2021

Change of Company Name

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 May 2021

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

1 item

– First NDA submission by HUTCHMED in the U.S.; product launch preparations underway – Hong Kong, Shanghai & Florham Park, NJ — Monday, May 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces th

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Apr 2021

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

1 item

— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and other NHL subtypes in the U.S., Europe an

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Apr 2021

Results of Annual General Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 28, 2021: Hutchison China MediTech Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual G

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Apr 2021

Vesting of awards under the Long Term Incentive Plan

1 item

Hong Kong, Shanghai & Florham Park, NJ: Friday, April 23, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 2

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Apr 2021

Notification of Dilution of Voting Rights

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in HUTCHMED remains unc

View Announcement (PDF)

Announcements & Press Releases, Group | 8 Apr 2021

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong, Shanghai & Florham Park, NJ — Thu

View Announcement (PDF)

1 2 3

5 6 7 8 9 10 11 12 13 14 15